The deal announcement initially drove a pop in Rite Aid's stock, but soon enough, retail investors, major shareholder Highfields Capital and advisory firms ISS and Glass Lewis opposed the deal on valuation, arguing little to no premium for Rite Aid. They claimed a merger of equals and rejected the 29-percent split, noting that the relative value of Albertsons, a private company, was up for debate.